Inflammatory bowel disease approaching the 3rd millennium: Pathogenesis and therapeutic implications?

European Journal of Gastroenterology and Hepatology

Volumn 11, Issue 1, 1999, Pages 27-32

  Ardizzone, Sandro ^a   Bollani, Simona ^a   Manzionna, Guendalina ^a   Porro, Gabriele Bianchi ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CLONIDINE; CYTOKINE; LIDOCAINE; NICOTINE;

CELL ADHESION; ENTERITIS; GENE THERAPY; GENETIC PREDISPOSITION; HEADACHE; HUMAN; INTESTINE FLORA; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKIN IRRITATION; THROMBOCYTE AGGREGATION INHIBITION; ULCERATIVE COLITIS; XEROSTOMIA;

EID: 0032976217     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199901000-00006     Document Type: Review

References (49)

1. Duerr R, Neigut D. Molecular defined HLA-DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 1995; 108:423-427.
2. Satsangi J, Welsh K, Bunce M, Julier C, Farrant JM, Bell JI, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996; 347:1212-1217.
3. Mansfield JC, Holden H, Tarlow JK, Di Giovane FS, McDowell IL, Wilson AG, et al. Novel genetic association between ulcerative colitis and the antiinflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994; 106:637-642.
4. Duerr R, Tran T. Association between ulcerative colitis and a polymorphism in intron 2 of the interleukin-1 receptor antagonist gene [Abstract]. Gastroenterology 1995; 108:A812.
5. Plevy S, Targan S, Yang H, Fernandez D, Rotter J, Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996; 110:1053-1060.
6. Hugot J, Laurent-Puig P, Gower-Rousseau C, Olson JH, Lee JC, Beaugerie L, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996; 379:821-823.
7. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Weish K, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosome 3, 7, and 12. Nature Genet 1996; 14:199-202.
8. Ledley FD. Somatic gene therapy in gastroenterology: approaches and applications. J Pediatr Gastroenterol Nutr 1992; 14:328-337.
9. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996; 334:316-318.
10. Hogaboam CM, Vallance BA, Kumar A, Addison CL, Graham FL, Gauldie J, et al. Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 1997; 100:2766-2776.
11. Mosman TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7:145-173.
12. Fuss IJ, Neurath M, Boirivant M, Klein JS, Delamotte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157:1261-1270.
13. Sands BE. Biological therapy for inflammatory bowel disease. Inflam Bowel Dis 1997; 3:95-113.
14. Deusch K, Mauthe B, Reiter C, Reithmüller G, Classen M. CD4-antibody treatment of inflammatory bowel disease: one year follow-up [Abstract]. Gastroenterology 1993; 104:A691.
15. Stronkhorst A, Radema S, Yong SL, Bijl H, Ten Berg UM, Tytgat GNJ, et al. CD4 antibody treatment in patients with active Crohn's disease: a phase I dose finding study. Gut 1997; 40:320-327.
16. Emmrich J, Seyfarth M, Fleig WE, Emmrich F. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 1991; 338:570-571.
17. Emmrich J, Seyfarth M, Liebe S, Emmrich F. Anti-CD6 antibody treatment in inflammatory bowel disease without a long CD4+-cell depletion [Abstract]. Gastroenterology 1995; 108:A815.
18. Canva-Delcambre V, Jacquot S, Robinet E, Lemann M, Drovet C, Labalette M, et al. Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 1996; 10:721-727.
19. Kühn R, Lohler J, Rennick D, Rajewski K, Müller W. Interleukin-10-deficient mice chronic enterocolitis. Cell 1993; 75:263-274.
20. Schreiber S, Heing T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-1444.
21. van Deventer Sjhelson CO, Fedorak RN, for the Crohn's Disease Study Group. Multiple doses of intravenous interleukin 10 in steroid refractory Crohn's disease. Gastroenterology 1997; 113:383-389.
22. Fedorak RN, Gangl A, Elson CO, Rutgeers P, Schreiber S, Wild G, et al. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (Stamm-CD). Presented at Digestive Disease Week, New Orleans, 17-20 May 1998:A4408.
23. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182:1281-1290.
24. Buhlmann JE, Noelle RJ. Therapeutic potential for blockade of the CD40 ligand, gp39. J Clin Immunol 1996; 16:83-89.
25. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106:533-539.
26. Lukacs NW, Chensue SW, Strieter RM, Warmington K, Kunkel SL. Inflammatory granuloma formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. J Immunol 1994; 152:5883-5889.
27. Cominelli F, Bortolami M, Pizzarro TT. Rabbit interleukin-1 receptor antagonist: cloning, expression, functional characterization, and regulation during intestinal inflammation. J Biol Chem 1994; 269:6962-6971.
28. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992; 103:65-71.
29. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:120-135.
30. Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997; 337:1029-1035.
31. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease. Lancet 1997; 349:521-524.
32. Geboes K, Ectors N. The infectious track in inflammatory bowel disease: a controversial area. Res Clin Forums 1995; 17:41-48.
33. Wakefield AJ, Ekbom A, Dhillon AP, Pittilo AP, Pittilo RM, Pounder R. Crohn's disease: pathogenesis and persistent measles virus infection. Gastroenterology 1995; 108:911-916.
34. Wakefield AJ, Pittilo RM, Sim R, Stephenson JR, Dhillon AP. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993; 39:345-353.
35. Fisher NC, Yee L, Nightingale P, McEwan R, Gibson JA. Measles virus serology in Crohn's disease. Gut 1997; 41:66-69.
36. Duchmann R, Kaisewr I, Hermann E, Mayet W, Ewe K, Meyer Zum Büschenfelde RH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:48-55.
37. Prantera C, Scribano ML, Berto E, Zannoni F. Antibiotic use in Crohn's disease. In: Clinical Challenges in Inflammatory Bowel Disease. Diagnosis, Prognosis and Treatment. Campieri M, Bianchi Porro G, Fiocchi C, Schölmerich J (editors). London: Kluwer Academic Publishers; 1998. pp. 153-160.
38. Gionchetti P, Rizzello F, Venturi A, Peruzzo S, Ferretti M, Rivalta C, et al. Probiotics and intestinal flora. In: Clinical Challenges in Inflammatory Bowel Disease. Diagnosis, Prognosis and Treatment. Campieri M, Bianchi Porro G, Fiocchi C, Schölmerich J (editors). London: Kluwer Academic Publishers; 1998. pp. 239-243.
39. Geboes K, Rutgeerts PJ. Vasculitis and Crohn's disease. Res Clin Forums 1995; 17:57-65.
40. Wakefield AJ, Sawyer AFM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AAM, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; ii:1057-1062.
41. Talbot RW, Hepel J, Dozois RR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986; 61:140-145.
42. Gaffny RR, Doyle CT, Gaffney A, Hogan J, Hayes DP, Annis P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterol 1995; 90:220-223.
43. Evans RC, Shim Wong V, Morris AL, Rhodes JM. Treatment of corticosteroid-resistant ulcerative colitis with heparin: a report of 16 cases. Aliment Pharmacol Ther 1997; 11:1037-1040.
44. Collins S. The immunomodulation of enteric neuromuscular function: implication for motility and inflammatory disorders. Gastroenterology 1996; 111:1683-1699.
45. Ottaway CA, Stanisz AM. Neural-immune interactions in the intestine: implications for inflammatory bowel disease. In: Inflammatory Bowel Disease, IVth Edn. Kirsner JB, Shorter RG (editors). Baltimore: Williams and Wilkins; 1995. pp. 281-300.
46. Bjork S, Dahlstrom A, Johansson L, Ahlman H. Treatment of the mucosa with local anaesthetics in ulcerative colitis. Agents Actions 1992; Special Conference Issue:C60-C75.
47. Arlander E, Ost A, Stahlberg D, Löfberg R. Ropivocaine gel in active distal ulcerative colitis and proctitis - a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996; 10:73-81.
48. Lechin F, Van der Dijs B, Insausti CL, Gomez F, Villa S, Lechin AE, et al. Treatment of ulcerative colitis with clonidine. J Clin Pharmacol 1985; 25:219-226.
49. Ardizzone S, Bollani S, Manzionna G, Maconi G, Furlan R, Vago L, Bianchi Porro G. Efficacy of transdermal clonidine for mild to moderate active left-sided ulcerative colitis: a pilot study. Gut, in press.